Eli Lilly and Company (LLY)
Healthcare · Drug Manufacturers - General · Data as of 2026-09-01
Bottom line
LLY is trading near its usual valuation, near its historical resistance zone, and recent volume suggests money flowing out. Historically, this combination has called for extra caution. Past patterns are not a guarantee of future results.
Valuation — Priced about in line with its growth (Yellow)
For a fast-growing company like LLY (revenue is growing about 45% a year), we weigh next year's expected P/E of 32× against the 28% earnings growth analysts expect (a forward PEG of 1.13, 15 estimates). That is a fairly typical trade-off. Its current multiple sits around the 9th percentile of its own last five years — toward the low end of its own range. About 71% of its reported earnings arrived as free cash over the last year.
Price zones — Near its historical resistance zone (Red)
At $1,160.00, the stock is close to the upper end of its recent range. Over the past year LLY has traded between $712.05 and $1,292.65; its historical support zone sits near $1,061.33 and resistance near $1,189.16. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $712.05–$1,292.65 · 50-day average $1,189.16 · 200-day average $1,061.33
Money flow — Money is flowing out (Red)
Recent trading in LLY shows more volume on falling days than rising days, a pattern often described as distribution. Volume on up days has been about 0.8× volume on down days over the last 30 sessions.
About the company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500).
一句话结论
LLY 估值接近其惯常水平，接近其历史阻力区，近期成交量显示资金正在流出。从历史来看，这样的组合需要格外谨慎。过去的形态并不能保证未来的结果。
估值 — 价格与其增长大致相称
对 LLY 这样的高增长公司（营收年增长约 45%），我们把它明年的预期市盈率 32× 与分析师预计的 28% 盈利增速放在一起看（前瞻 PEG 为 1.13，来自 15 份预测）。这是相当常见的一种取舍。它当前的估值倍数大约位于自身过去五年分布的第 9 百分位——处于自身区间的偏低位置。过去一年，其报告利润中约有 71% 转化为自由现金。
价格区间 — 接近其历史阻力区
目前价格为 $1,160.00，接近其近期区间的上沿。过去一年 LLY 的价格在 $712.05 到 $1,292.65 之间波动；其历史支撑区在 $1,061.33 附近，阻力区在 $1,189.16 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 资金正在流出
LLY 近期下跌日的成交量高于上涨日，这种形态常被称为派发。过去 30 个交易日，上涨日的成交量约为下跌日的 0.8×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.